Unmasking a hepatitis C genotype 3a/1b dual infection in an individual treated with elbasvir/grazoprevir

Pan-genotypic direct-acting antivirals (DAA) for the treatment of hepatitis C viral (HCV) infections remain expensive. To reduce costs, genotype-specific regimes could be considered, according to the EASL guidelines.1 The presence of mixed genotype HCV infections has been reported, and detection rates have been found to be method dependent.2 The identification of a second infection with a different genotype could be of importance when considering genotype specific DAA.